WallStreetZenWallStreetZen

NYSEMKT: ATNM
Actinium Pharmaceuticals Inc Earnings & Revenue

OverviewForecastEarnings
DividendOwnership

ATNM past revenue growth

How has ATNM's revenue growth performed historically?
Company
-92.14%
Industry
153.85%
Market
17.91%
ATNM's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
ATNM's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance

ATNM earnings and revenue history

Current Revenue
$81.0k
Current Earnings
-$48.8M
Current Profit Margin
-60,269.1%

ATNM Return on Equity

Current Company
-102.6%
Current Industry
-63.5%
Current Market
188%
ATNM's Return on Equity (-102.6%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when ATNM announces earnings.

ATNM Return on Assets

Current Company
-52.6%
Current Industry
2.9%
ATNM is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

ATNM Return on Capital Employed

Current Company
-66.92%
Current Industry
19.5%
ATNM's ability to generate Return... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

ATNM vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
ATNM$81.00k-$48.03M-$48.82M-73.39%N/A
ALDX$0.00-$35.21M-$37.54MN/AN/A
CDT$0.00-$324.00k-$535.00kN/AN/A
INO$832.01k-$130.39M-$135.12M-51.33%N/A
QURE$15.84M-$253.10M-$308.48M+7.02%N/A
View Top Biotech Stocks

ATNM earnings dates

Next earnings date
May 15, 2024

Actinium Pharmaceuticals Earnings & Revenue FAQ

What were ATNM's earnings last quarter?

On Invalid Date, Actinium Pharmaceuticals (NYSEMKT: ATNM) reported Q4 2023 earnings per share (EPS) of -$0.33, up 23.26% year over year. Total Actinium Pharmaceuticals earnings for the quarter were -$9.32 million. In the same quarter last year, Actinium Pharmaceuticals's earnings per share (EPS) was -$0.43.

If you're new to stock investing, here's how to buy Actinium Pharmaceuticals stock.

What was ATNM's earnings growth in the past year?

As of Q2 2024, Actinium Pharmaceuticals's earnings has grown year over year. Actinium Pharmaceuticals's earnings in the past year totalled -$48.82 million.

What is ATNM's earnings date?

Actinium Pharmaceuticals's earnings date is Invalid Date. Add ATNM to your watchlist to be reminded of ATNM's next earnings announcement.

What was ATNM's revenue last quarter?

On Invalid Date, Actinium Pharmaceuticals (NYSEMKT: ATNM) reported Q4 2023 revenue of $81.00 thousand up Infinity% year over year. In the same quarter last year, Actinium Pharmaceuticals's revenue was $0.00.

What was ATNM's revenue growth in the past year?

As of Q2 2024, Actinium Pharmaceuticals's revenue has grown -92.14% year over year. This is 245.99 percentage points lower than the US Biotechnology industry revenue growth rate of 153.85%. Actinium Pharmaceuticals's revenue in the past year totalled $81.00 thousand.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.